Yüklüyor......
Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy
Psoriasis is a chronic inflammatory disorder that is clinically characterized by scaly cutaneous plaques. New evidence suggests that dysregulation of interleukin (IL)-23, a key cytokine in the T-helper-17 pathway, plays a vital role in the development of psoriatic systemic inflammation. The novel bi...
Kaydedildi:
| Yayımlandı: | Ther Adv Chronic Dis |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6691657/ https://ncbi.nlm.nih.gov/pubmed/31448070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622319865658 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|